Back to Directory Claudine Gregorio Email ClaudineGregorio@westat.com Phone 919-596-1423 Institution Westat Request an Update Affiliated Studies IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV. DAIDS Number 38747 Research Area Tuberculosis Study Status Open to Accrual IMPAACT 2050: CREATE DAIDS Number 39208 Research Area Treatment Study Status Pending
IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV. DAIDS Number 38747 Research Area Tuberculosis Study Status Open to Accrual
